Tsuyoshi Saito

Tsuyoshi Saito

Auto-generated profile, based on publicly available information

Tsuyoshi Saito

Department of Surgery, Japanese Red Cross Saitama Hospital, Saitama, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NTNaruto Taira
Naruto Taira
MSMasataka Sawaki
Masataka Sawaki
YUYukari Uemura
Yukari Uemura
TSTsuyoshi Saito
Tsuyoshi Saito
SBShinichi Baba
Shinichi Baba
FGfor the RESPECT Study Group
for the RESPECT Study Group
PURPOSEWe report findings on quality of life (QoL) in the RESPECT trial, which compared adjuvant trastuzumab monotherapy with trastuzumab plus chemotherapy in older patients with human epidermal gr...

1 February 2021 in The Breast
Verified
Journal Article
Open access
JUNJI TSURUTANIJUNJI TSURUTANI
JUNJI TSURUTANI
FHFumikata Hara
Fumikata Hara
MKMasahiro Kitada
Masahiro Kitada
MTMasato Takahashi
Masato Takahashi
YKYuichiro Kikawa
Yuichiro Kikawa
HMHirofumi Mukai
Hirofumi Mukai
Chemotherapy-induced peripheral neuropathy is commonly observed in patients treated with nanoparticle albumin–bound paclitaxel (nab-PTX). We conducted a multicenter randomized controlled study to evaluate the optimal dose of nab-PTX. We compared three different doses of q3w nab-PTX (Standard: 260 mg/m2 [SD260] vs Medium: 220 mg/m2 [MD220] vs Low: 180 mg/m2 [LD180]) in patients with HER2-negative metastatic breast cancer (MBC). Primary endpoint was progression-free survival (PFS). Grade 3/4 neuropathy rates in the three doses were estimated using the logistic regression model. The optimal dose was selected in two steps. Initially, if the hazard ratio (HR) for PFS was 1.33, the inferior dose was excluded, and we proceeded with the non-inferior dose. Then, if the estimated incidence rate of grade 3/4 neurotoxicity exceeded 10%, that dose was also excluded. One hundred forty-one patients were randomly assigned to SD260 (n = 47), MD220 (n = 46), and LD180 (n = 48) groups, and their median PFS was 6.66, 7.34, and 6.82 months, respectively. The HRs were 0.73 (95% confidence interval [CI]: 0.42–1.28) in MD220 vs SD260, 0.77 (95% CI 0.47–1.28) in LD180 vs SD260, and 0.96 (95% CI 0.56–1.66) in LD180 vs MD220. SD260 was inferior to MD220 and was excluded. The estimated incidence rate of grade 3/4 neurotoxicity was 29.5% in SD260, 14.0% in MD220, and 5.9% in LD180. The final selected dose was LD180. Intravenous administration of low-dose nab-PTX at 180 mg/m2 q3w may be the optimal therapy with meaningful efficacy and favorable toxicity in patients with MBC.